Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening, acquired disease in which blood cells lacking complement regulatory proteins are destroyed because of uncontrolled complement activity. Since 2007, terminal complement inhibitors have revolutionized the treatment of this disease....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood reviews 2023-05, Vol.59, p.101041-101041, Article 101041
Hauptverfasser:	Kulasekararaj, Austin G., Kuter, David J., Griffin, Morag, Weitz, Ilene C., Röth, Alexander
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Biomarkers Complement C3 - metabolism Complement Inactivating Agents - pharmacology Complement Inactivating Agents - therapeutic use Complement inhibitor Extravascular hemolysis Hemoglobin Hemoglobinuria, Paroxysmal - diagnosis Hemoglobinuria, Paroxysmal - drug therapy Hemolysis Humans Intravascular hemolysis Lactate dehydrogenase Paroxysmal nocturnal hemoglobinuria
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!